Scribe Therapeutics Inc. Common Stock (SCTX) - Total Liabilities
Based on the latest financial reports, Scribe Therapeutics Inc. Common Stock (SCTX) has total liabilities worth $222.77 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Scribe Therapeutics Inc. Common Stock defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Scribe Therapeutics Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Scribe Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check SCTX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Scribe Therapeutics Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Scribe Therapeutics Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
China | CN¥407.64 Million |
|
SPCG Public Company Limited
BK:SPCG
|
Thailand | ฿367.68 Million |
|
GDI Integrated
TO:GDI
|
Canada | CA$762.00 Million |
|
V.S.T Tillers Tractors Limited
NSE:VSTTILLERS
|
India | Rs-10.94 Billion |
|
Y mAbs Therapeutics
NASDAQ:YMAB
|
USA | $29.72 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩239.83 Billion |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
China | CN¥1.15 Billion |
|
Issta Lines Ltd
TA:ISTA
|
Israel | ILA2.29 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Scribe Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SCTX total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scribe Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Scribe Therapeutics Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $221.64 Million | -12.68% |
| 2024-12-31 | $253.83 Million | -- |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more